-
Something wrong with this record ?
Association among serum per- and polyfluoroalkyl substances, lipid profile and metabolic syndrome in Czech adults, HBM-EHES survey 2019
V. Puklová, N. Čapková, A. Fialová, A. Vavrouš, K. Žejglicová, M. Černá
Language English Country Czech Republic
Document type Journal Article
Digital library NLK
Source
NLK
Free Medical Journals
from 2004
ProQuest Central
from 2009-03-01 to 6 months ago
Medline Complete (EBSCOhost)
from 2006-03-01 to 6 months ago
Nursing & Allied Health Database (ProQuest)
from 2009-03-01 to 6 months ago
Health & Medicine (ProQuest)
from 2009-03-01 to 6 months ago
Public Health Database (ProQuest)
from 2009-03-01 to 6 months ago
ROAD: Directory of Open Access Scholarly Resources
from 1993
PubMed
38309699
DOI
10.21101/cejph.a7799
Knihovny.cz E-resources
- MeSH
- Cholesterol MeSH
- Adult MeSH
- Fluorocarbons * MeSH
- Alkanesulfonic Acids * MeSH
- Decanoic Acids * MeSH
- Sulfonic Acids * MeSH
- Environmental Pollutants * MeSH
- Humans MeSH
- Lipids MeSH
- Metabolic Syndrome * epidemiology MeSH
- Serum MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
OBJECTIVES: Per- and polyfluoroalkyl substances (PFASs) are a large group of persistent synthetic chemicals widely used commercially. They accumulate increasingly in all environmental components and enter the organisms, including humans. Some of them are associated with the risk of harm to health, among others with metabolic disorders. To test the associations between blood serum levels of PFASs and blood lipid profile as well as metabolic syndrome, we linked human biomonitoring with the Czech Health Examination Survey (CZ-EHES) conducted in 2019. METHODS: A total of 168 participants of the CZ-EHES survey aged 25-64 years were examined including anthropometrical data and analyses for serum PFAS and blood lipid levels. Extended model approach in multiple linear regression models was used for identification of the associations between serum levels of 11 PFASs and lipid profile components. The relation between PFAS serum levels and metabolic syndrome prevalence was tested using a logistic regression model. RESULTS: Six PFASs were detected over the limit of quantification in at least 40% cases and were examined in subsequent analyses: perfluorodecanoic acid (PFDA), perfluorohexane sulfonic acid (PFHxS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorooctane sulfonic acid (PFOS), perfluoroundecanoic acid (PFUdA). The most dominant was PFOS with the mean value amounting to 4.81 ng/ml. After adjusting for potential confounders, we found a significant positive association between serum PFHxS and blood total cholesterol (p = 0.005) as well as LDL-cholesterol (p = 0.008). Significant positive association was also found between PFDA and HDL-cholesterol levels (p = 0.010). No significant associations were detected between PFASs and triglycerides, and between PFASs and metabolic syndrome. CONCLUSIONS: We found some evidence of a significant association between blood serum PFAS levels and blood cholesterol levels. Our results did not confirm an association between serum PFASs and the metabolic syndrome prevalence.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24002925
- 003
- CZ-PrNML
- 005
- 20250312094528.0
- 007
- ta
- 008
- 240215s2023 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21101/cejph.a7799 $2 doi
- 035 __
- $a (PubMed)38309699
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Puklová, Vladimíra $u National Institute of Public Health, Prague, Czech Republic $7 mzk2007408334
- 245 10
- $a Association among serum per- and polyfluoroalkyl substances, lipid profile and metabolic syndrome in Czech adults, HBM-EHES survey 2019 / $c V. Puklová, N. Čapková, A. Fialová, A. Vavrouš, K. Žejglicová, M. Černá
- 520 9_
- $a OBJECTIVES: Per- and polyfluoroalkyl substances (PFASs) are a large group of persistent synthetic chemicals widely used commercially. They accumulate increasingly in all environmental components and enter the organisms, including humans. Some of them are associated with the risk of harm to health, among others with metabolic disorders. To test the associations between blood serum levels of PFASs and blood lipid profile as well as metabolic syndrome, we linked human biomonitoring with the Czech Health Examination Survey (CZ-EHES) conducted in 2019. METHODS: A total of 168 participants of the CZ-EHES survey aged 25-64 years were examined including anthropometrical data and analyses for serum PFAS and blood lipid levels. Extended model approach in multiple linear regression models was used for identification of the associations between serum levels of 11 PFASs and lipid profile components. The relation between PFAS serum levels and metabolic syndrome prevalence was tested using a logistic regression model. RESULTS: Six PFASs were detected over the limit of quantification in at least 40% cases and were examined in subsequent analyses: perfluorodecanoic acid (PFDA), perfluorohexane sulfonic acid (PFHxS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorooctane sulfonic acid (PFOS), perfluoroundecanoic acid (PFUdA). The most dominant was PFOS with the mean value amounting to 4.81 ng/ml. After adjusting for potential confounders, we found a significant positive association between serum PFHxS and blood total cholesterol (p = 0.005) as well as LDL-cholesterol (p = 0.008). Significant positive association was also found between PFDA and HDL-cholesterol levels (p = 0.010). No significant associations were detected between PFASs and triglycerides, and between PFASs and metabolic syndrome. CONCLUSIONS: We found some evidence of a significant association between blood serum PFAS levels and blood cholesterol levels. Our results did not confirm an association between serum PFASs and the metabolic syndrome prevalence.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a látky znečišťující životní prostředí $7 D004785
- 650 12
- $a metabolický syndrom $x epidemiologie $7 D024821
- 650 _2
- $a sérum $7 D044967
- 650 _2
- $a lipidy $7 D008055
- 650 12
- $a fluorokarbony $7 D005466
- 650 _2
- $a cholesterol $7 D002784
- 650 12
- $a kyseliny dekanové $7 D003652
- 650 12
- $a kyseliny sulfonové $7 D013451
- 650 12
- $a kyseliny alkansulfonové $7 D017738
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Čapková, Naďa $u National Institute of Public Health, Prague, Czech Republic $7 xx0093653
- 700 1_
- $a Fialová, Alena $u National Institute of Public Health, Prague, Czech Republic $u Third Faculty of Medicine, Charles University in Prague, Czech Republic $7 stk2008461869
- 700 1_
- $a Vavrouš, Adam $u National Institute of Public Health, Prague, Czech Republic $7 _AN087637
- 700 1_
- $a Žejglicová, Kristýna $u National Institute of Public Health, Prague, Czech Republic $7 xx0088521
- 700 1_
- $a Černá, Milena, $d 1943- $u National Institute of Public Health, Prague, Czech Republic $u Third Faculty of Medicine, Charles University in Prague, Czech Republic $7 nlk19990074185
- 773 0_
- $w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 31, č. 4 (2023), s. 227-234
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38309699 $y Pubmed
- 910 __
- $a ABA008 $b B 1829 $c 562 $y p $z 0
- 990 __
- $a 20240215 $b ABA008
- 991 __
- $a 20250312094535 $b ABA008
- 999 __
- $a ok $b bmc $g 2283461 $s 1212661
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 31 $c 4 $d 227-234 $e - $i 1210-7778 $m Central European journal of public health $n Cent Eur J Public Health $x MED00001083
- LZP __
- $b NLK124 $a Pubmed-20240215